Novel Selenoesters as a Potential Tool in Triple-Negative Breast Cancer Treatment

Disturbing cancer statistics, especially for breast cancer, are becoming a rationale for the development of new anticancer therapies. For the past several years, studies have been proving a greater role of selenium in the chemoprevention of many cancers than previously considered; hence, a trend to...

ver descrição completa

Detalhes bibliográficos
Autores: Radomska, Dominika, Czarnomysy, Robert, Szymanowska, Anna, Radomski, Dominik, Domínguez-Álvarez, Enrique, Bielawska, Anna, Bielawski, Krzysztof
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2022
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/285730
Acesso em linha:http://hdl.handle.net/10261/285730
Access Level:Acceso aberto
Palavra-chave:Breast cancer
triple-negative breast cancer
anticancer drugs
selenium compounds
organoselenium compounds
selenoesters
apoptosis
Cell signaling
flow cytometry
Descrição
Resumo:Disturbing cancer statistics, especially for breast cancer, are becoming a rationale for the development of new anticancer therapies. For the past several years, studies have been proving a greater role of selenium in the chemoprevention of many cancers than previously considered; hence, a trend to develop compounds containing this element as potential agents with anticancer activity has been set for some time. Therefore, our study aimed to evaluate the anticancer activity of novel selenoesters (EDA-71, E-NS-4) in MCF-7 and MDA-MB-231 human breast cancer cells. The assays evaluating proliferation and cell viability, and flow cytometer analysis of apoptosis/autophagy induction, changes in mitochondrial membrane potential, disruption of cell cycle phases, and protein activity of mTOR, NF-κB, cyclin E1/A2, and caspases 3/7, 8, 9, 10 were performed. The obtained results indicate that the tested selenoesters are highly cytotoxic and exhibit antiproliferative activity at low micromolar doses (<5 µM) compared with cisplatin. The most active compound—EDA-71—highly induces apoptosis, which proceeds via both pathways, as evidenced by the activation of all tested caspases. Furthermore, we observed the occurrence of autophagy (↓ mTOR levels) and cell cycle arrest in the S or G/M phase (↓ cyclin E1, ↑ cyclin A2).